HPV-16 E7 is under clinical development by Gilead Sciences and currently in Phase II for Oropharyngeal Cancer.

Sacituzumab govitecan is under clinical development by Gilead Sciences and currently in Phase II for Papillary Thyroid Cancer.

Gilead Sciences bought nearly 950,000 more shares of antiviral-therapeutics developer Assembly as part of an amended ...

Gilead stock rated buy for thriving HIV biz, promising oncology pipeline, and long-term growth potential despite volatility.

We recently compiled a list of the Jim Cramer Talked About These 8 Stocks. In this article, we are going to take a look at ...

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

Gilead Sciences Inc (GILD) stock saw a decline, ending the day at $94.11 which represents a decrease of $-0.30 or -0.32% from the prior close of $94.41. The stock opened at $93.43 and touched a low of ...

The stock's fall snapped a five-day winning streak.

Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company, discovers, develops and commercializes medicines to address ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...